Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Asciminib (ABL001) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (Blood Dec 2014, 124 (21) 398).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Asciminib||Scemblix||ABL001|ABL-001||BCR-ABL Inhibitor 28||Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02081378||Phase I||Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib||A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL||Active, not recruiting||USA | ITA | FRA | ESP | DEU||5|
|NCT04216563||Phase II||Asciminib||ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor||Recruiting||USA||0|
|NCT04666259||Phase III||Asciminib||Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)||Recruiting||USA||0|
|NCT04948333||Phase III||Asciminib||Asciminib Treatment Optimization in >= 3rd Line CML-CP.||Recruiting||ITA | FRA | ESP | DEU | CAN | AUT||8|
|NCT05143840||Phase II||Asciminib Asciminib + Nilotinib||Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase||Recruiting||USA||0|
|NCT04971226||Phase III||Asciminib Bosutinib Imatinib Dasatinib Nilotinib||A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||21|
|NCT03106779||Phase III||Bosutinib Asciminib||Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs||Active, not recruiting||USA | ITA | FRA | ESP | DEU | CAN||19|
|NCT04925479||Phase Ib/II||Asciminib||Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia||Recruiting||USA | ITA | FRA | DEU||7|